Allen Institute for Immunology
In collaboration with the Allen Institute for Immunology, BRI is studying the healthy immune system in an unprecedented way, recruiting healthy adults in the age ranges of 25-35 and 55-65 from the Seattle area to enroll in a one-year research partnership to understand healthy immune systems. This effort will shed light on a variety of factors that can impact the immune system from genetics to lifestyle to environmental factors. If you’re interested in being considered for this pioneering research initiative, please sign up for the Healthy Volunteer Biorepository.
Parker Institute for Cancer Immunotherapy
Immunotherapy has become a first-line treatment for several types of cancer. Over time, researchers have observed that some patients develop autoimmune disorders following cancer immunotherapy. After treatment with checkpoint inhibitors, for example, roughly 1% develop a kind of insulin-dependent diabetes that appears similar to type 1 diabetes (T1D), according to research published in the journal Diabetes.
The Parker Institute for Cancer Immunotherapy, JDRF and The Leona M. and Harry B. Helmsley Charitable Trust have partnered in a collaborative research initiative to better understand this phenomenon and to identify the causes of T1D. The three nonprofits are jointly funding $10 million in autoimmunity research over a three-year period. Jane Buckner, M.D., president and director of translational research at BRI is one of the partnering investigators in this initiative.
In partnership with JDRF, BRI is home to the JDRF Core for Clinical Assay Validation (CAV), which plays an important role in identifying T1D biomarkers and in helping outside researchers get the most accurate test results. The CAV is pinpointing key T1D biomarkers, such as markers that indicate which patients with T1D will keep making insulin for years and which patients won’t.